genetics in ontario: mapping the future

Genetics in Ontario:Mapping the Future

Anne Summers MD

Chair, Ontario Provincial AdvisoryCommittee on New Predictive

Genetic Technologies

Genetics in Ontario: Mapping the Future

• Issues in providing genetic services in Canada

• Impact of change in genetics– on medicine– on society – on government

• The work of the Provincial Advisory Committee

Issues in providing Genetic Services in Canada

• Evolution of Genetics

• The Canada Health Act

• Geography

‘OLD’ GENETICS

‘NEW’ GENETICS

Type of tests Mainly diagnostic

Mainly predictive

Type of disorders

Rare disordersMainly paediatricUsually a high chance of having or developing the disorder

Common disorders - genetic componentMainly adult-onsetLow to high chance of developing the disorder

Type of results

Usually, but not always, confirm presence of disease but not severity

More complex risk predictions which may involve gene(s) and environment

The Evolution of Genetics

Traditional Genetics Practice

• Patients usually seen by geneticists and genetic counsellors

• Counselling re: recurrence risks and reproduction

• New tests introduced on an ad hoc basis

• Very little specific treatment

The ten leading causes of death in Canada (1997)

Cancers (58,703 deaths) Heart disease (57,417) Cerebrovascual diseases (16,051) Chronic Obstructive Pulmonary Disease (COPD)

(9,618) Injury (8,626) Pneumonia/influenza (8,032) Diabetes (5,699) Neurogenerative diseases (5,049) Diseases of blood vessels (4,767) Psychoses (4,645).

New GeneticPractice

• More involvement of family physicians and non-geneticist specialists

• Complicated results• Treatment more likely

– lifestyle changes– conventional therapy– gene therapy– pharmacogenetics

Canada Health Act (1984)

• Public administration - non-profit HIP’s

• Comprehensiveness - all insured services covered

• Portability - between provinces• Universality - everyone covered• Accessibility - to all

Genetic Centres in Ontario

.. . ...

.

........ .

..

Thunder Bay

Toronto

Ottawa

London

Windsor

TimminsSault Ste MarieSudbury

Kingston

Impact of Change in Genetics on Medicine

• More involvement of family physicians and non-genetics specialists.

• Prediction vs. diagnosis• Increased complexity of risk calculations.• Pre- and post-test counselling• Long term follow-up• Psychological effects• Ethical concerns

Impact of Change in Genetics on Society

• Need for a better understanding of genetics including risk

• Difference between prediction and diagnosis

• Testing for disease vs. traits• Ethical issues – discrimination,

privacy, confidentiality, coercion

Impact of Change in Genetics on Government

• Must reflect the views of society• Public debate on genetic issues• Funding of new or expanded

services – testing, counselling, downstream costs

• Legislation and regulation where required

Ontario Provincial Advisory Committee on New Predictive

Genetic Technologies

• develop principles/guidelines/broad criteria to guide operational decision making by the MOHLTC in introducing new genetic predictive technologies in Ontario.

• The breadth of expertise required for the committee must include expertise across the broad array of clinical, technical, financial, psychosocial, ethical and legal concerns.

Ontario Provincial Advisory Committee

• geneticists • genetic counsellor • family physicians • genetic researchers • laboratory directors • clinical epidemiologist • academics in law, ethics and medicine • educators


• An expert in psychosocial issues• Representative of the private sector• Representatives from the Canadian

Cancer Society, the Huntington Society of Canada, and the Heart and Stroke Foundation

• Representatives from the the Ministry of Health and Long-Term Care


• Committee announced by Minister of Health – April 19, 2000

• First meeting – Sept, 2000• Subcommittee work – Sept, 2000 to

Sept, 2001• First draft of report – Oct, 2001• Final report with subcommittee reports

to Minister of Health – Nov. 29, 2001


• Subcommittees:– Ethical/Legal– Evaluation– Laboratory– Clinical– Psychosocial– Education

Ethical/Legal Subcommittee

• Privacy and confidentiality• Informed consent/coercion• Discrimination• Allocation of resources• Patents, commercial use and direct

marketing of genetic testing• Storage of genetic information and

material• Microarrays

Evaluation subcommittee

• technical accuracy (analytical validity)• clinical effectiveness (clinical validity)• usefulness to tested individuals

(clinical utility) • adverse and additional effects• expansion potential• cost (social utility)

Laboratory subcommittee

• Appropriate and new technology• Quality assurance and regulatory

issues• Laboratory licensing• Specimen and data management• Development of laboratory expertise• Necessary volumes/test • Standardized reporting• Role of the private sector

Clinical subcommittee

• Eligibility criteria for referral and testing

• Access to testing and related services• Management of persons changing

from at-risk to affected status• Service standards and requirements• Pre- and post-test counselling, and

patient follow up• Regulatory requirements

Psychosocial subcommittee

• Integration of psychosocial support services into genetics services with ongoing quality assurance.

• Recommendations for screening persons at risk requiring psychosocial counselling

• Management of persons changing from at-risk to affected status

Education subcommittee

• Multifaceted approach to genetics education

• Public – throughout educational years and also in post-educational years

• Professionals – all areas of health care

• Patients – specific disorders

OPACNGT - Recommendations

1. An ongoing provincial genetics advisory committee

2. An evaluation process– evaluation of services - legal, ethical, social,

psychosocial, epidemiological, clinical and laboratory components

– balance costs of new genetic test vs. other prevention strategies

– guidelines and care maps in the genetic management of the condition.


3. Programmatic Genetic Services – integrated, multidisciplinary service– genetic assessment and counselling– quality testing – psychosocial support – follow-up services

• including surveillance, prevention and treatment


4. Education and Information– public education– professional education at all

levels– information on new genetic

services for providers and public


5. Quality– The pretest preparation (counselling,

education materials, etc.)– Analytical (laboratory tests and their

interpretation)– Post-analytical follow-up (interpretation

and reporting to patients)– Patient monitoring following testing– Ensure for OOP testing


6. Human Resources– encourage retention and recruitment

of personnel to genetics training programs

– introduce or enhance accredited training programs for genetic services

– ensure that all personnel directly involved in genetic services work in a regulated health environment


7. Non-discrimination– amend the Human Rights Code to

prevent discrimination on the basis of genetic traits

– approval system for the use of genetic testing and information in insurance, employment, etc.


8. Research– all genetic testing undertaken in the

research context in Ontario will have thorough research ethics review by independent and accountable research ethics boards.


9. Patents, direct marketing and commercialization of tests– The committee recommends that the

government of Ontario engage in discussions with the government of Canada regarding patents, direct to consumer marketing and other areas of federal jurisdiction related to the commercial use of genetic tests.


10. Informed Consent– informed consent with regard to predictive

genetic testing should be express and documented

11. Duty to Warn.– should not be a duty to disclose genetic

information to high risk relatives. – issue of physician privilege to disclose genetic

information to an individual’s high-risk relatives against his or her wishes, should be reviewed.


12. Privacy and Confidentiality• laboratory testing, blood and tissue samples• collection and storage of genetic information• access to stored genetic data/samples• tested individual’s right to request that his or

her DNA sample be destroyed• banking of newborn screening data/samples• standards of confidentiality regarding an

individual’s genetic information as relates to other family members

• the creation and treatment of genetic records as distinct from medical records.


13. Genetic Testing of Minors– no testing where there are no timely

medical or psychosocial benefits – generally, parental consent for

newborn genetic screening– when banking newborn screening

data and samples, individual rights of privacy and confidentiality are protected and that informed consent is integral to this practice.


Dr. Judith Allanson Grace Maddox Sharon Balsys Roxanne MykitiukDr. Sean Blaine Leela PrasaudDr. George Browman Dr. Kenneth PritzkerDr. June Carroll Maureen ProvencherDr. David Cole Francine Robert, BScNDr. Colin D'Cunha Dr. Kirsten RottenstenDr. Mary Jane Esplen Dr. Brian Sheridan, Dr. Alasdair Hunter Dr. Anne Summers Phil Jackson Elaine M.W.TaylorDr. Birthe Jorgensen Adam Topp Michael Kilpatrick Luke A. VannesteTrudo Lemmens Dr. Lea Velsher Dr. Les Levin Charlotte WeissDr. Alex MacKenzie Dr. Philip Wyatt

genetics in ontario: mapping the future

Documents

genetic services

canada evolution of

new genetic practice

genetic centres

genetic issues funding

nongenetics specialists

canada impact of change

future issues